Sponsor content
342 result(s) found, displaying 11 to 20
-
Australian Public Assessment Report (AusPAR)Kavigale (sipavibart) has been approved for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who are immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments.
-
Prescription medicine registrationActive ingredients: acalabrutinib maleate monohydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FLUMIST influenza virus vaccine 10,000,000 FFU/strain (0.2mL) nasal spray applicator.
-
Feb-2026Prescription medicine evaluationActive ingredient: baxdrostat.
-
Feb-2026Prescription medicine evaluationActive ingredient: datopotamab deruxtecan.
-
-
Designation or determinationPriority review
-
Jan-2026Prescription medicine evaluationActive ingredient: trastuzumab deruxtecan.
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
Prescription medicine registrationActive ingredients: Influenza virus.